Clinical trials
Completed Hypercholesterolemia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
295 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 12 |
| 2003 | 7 |
| 2004 | 9 |
| 2005 | 12 |
| 2006 | 11 |
| 2007 | 14 |
| 2008 | 16 |
| 2009 | 10 |
| 2010 | 10 |
| 2011 | 22 |
| 2012 | 26 |
| 2013 | 24 |
| 2014 | 9 |
| 2015 | 8 |
| 2016 | 18 |
| 2017 | 13 |
| 2018 | 10 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 12 |
| 2022 | 11 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 295 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 24 |
| Sanofi | 18 |
| Esperion Therapeutics, Inc. | 15 |
| AstraZeneca | 10 |
| National Heart, Lung, and Blood Institute (NHLBI) | 10 |
| Pfizer | 10 |
| Regeneron Pharmaceuticals | 10 |
| Novartis Pharmaceuticals | 8 |
| Daiichi Sankyo | 7 |
| Kastle Therapeutics, LLC | 7 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypercholesterolemia | 295 |
| Dyslipidemias | 45 |
| Hyperlipidemias | 44 |
| Hypertension | 40 |
| Diabetes Mellitus | 32 |
| Atherosclerosis | 24 |
| Cardiovascular Diseases | 22 |
| Obesity | 21 |
| Hyperlipoproteinemia Type II | 20 |
| Diabetes Mellitus, Type 2 | 11 |
Trials
Showing 1 to 25 of 295. Each trial links to its page on Pharma Observatory.
195 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.